Only an early diagnosis of the nodular goiter together with an up-to-date treatment can cure TM patients in a high percentage and prevent development of a terminal stage of the disease which is extremely severe in all forms of this malignancy.
Background: Well-known fact is that the good surgical treatment, leaving only small residuals of thyroid tissue, is the outmost valid predictive factor of successful ablative radioiodine treatment. Assuming that all patients had state of the art surgical treatment, with this study we tried to evaluate other possible predictive factors of successful radioiodine therapy after total thyroidectomy. Methods: Total of 56 patients (15 males and 41 females mean age 43.37±13), operated during the year 2001 was evaluated. Due to differentiated carcinoma of the thyroid total thyreoidectomy was done in 7 with follicular and in 49 patients with papillary cancer. Forty-one patients received ablative 131 I dose (3.7GBq) and fifteen patients received therapeutic dose (5.55GBq) of radioiodine therapy. As possible predictive factors the TNM classification (T1, 6; T2, 17; T3, 4; T4, 28 and 24 with N0 and 32 with N1), the number of foci on whole body scan (WBS), and the serum level of thyroglobulin were statistically evaluated. One year after radioiodine therapy control WBS was done and successful outcome of the therapy was considered to be the WBS without visible accumulation of radioiodine and with low serum level of thyroglobulin. Results: Outcome of ablative radioiodine therapy was considered as successful in 55.4% patients and 44.6% of patients needed additional radioiodine therapies. Only the number of foci and the level of thyroglobulin showed statistically significant (p(0.05) influence on the outcome of applied radioiodine therapy. Conclusion: Significant influence of the thyroglobulin level and number of foci on the WBS in patients with total thyroidectomy could be explained by the fact that there were the signs of minimum thyroid residual tissue, and that there were no microscopic spread of disease
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.